Evidence map›Paper›PMID 40966379›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

CircPVT1 Promotes Lung Metastasis and Tumor Progression in Renal Cell Carcinoma by Encoding the cP104aa Peptide and Targeting EIF4A3.

Houliang Zhang, Tao Tao, Jie Ji, Tonglei Zhao, Si Sun, Lijie Zhang, Jianping Wu, Ming Chen, Shuqiu Chen, Bin Xu and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. SPP1Journal for immunotherapy of cancer · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Houliang ZhangDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Tao TaoDepartment of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
Jie JiDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Tonglei ZhaoDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Si SunDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Lijie ZhangDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Jianping WuDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Ming ChenDepartment of Urology, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, 211200, China.
Shuqiu ChenDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Bin XuDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.
Weipu MaoDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China.ORCID https://orcid.org/0000-0002-3878-5224

Funding

Jiangsu Provincial Medical Key Discipline ZXKT-2023YXZDXK02National Natural Science Foundation of China 82403602Natural Science Foundation of Jiangsu Province BK20230842Natural Science Foundation of Jiangsu Province BK20231422Research Personnel Cultivation Programme of Zhongda Hospital Southeast University CZXM-GSP-RC60SEU Innovation Capability Enhancement Plan for Doctoral Students CXJH_SEU 25230
6 · The paper itself

Abstract

Circular RNA (circRNA) plays a pivotal role in the pathogenesis of renal cell carcinoma (RCC). CircRNAs regulate gene expression via RNA-binding proteins (RBPs) and also exert biological effects through peptide encoding. CircPVT1 has been previously identified as an oncogenic circRNA. This study identified that circPVT1 encodes a 104-amino acid peptide, termed cP104aa. Functional assays showed that circPVT1 and the cP104aa peptide enhance RCC cell proliferation, invasion, migration, and lung metastasis both in vitro and in vivo. Mechanistically, the cP104aa peptide interacts with HNRNPK, leading to reduced c-MYC ubiquitination and increased c-MYC expression. Additionally, circPVT1 directly associates with EIF4A3, facilitating the expression of the target gene c-MYC. Furthermore, axitinib is shown to target the degradation of the cP104aa peptide. These findings reveal a novel mechanism by which circPVT1 contributes to RCC, highlighting the potential of the cP104aa peptide as a therapeutic target. Axitinib may serve as an effective therapeutic agent for patients with advanced RCC exhibiting high cP104aa expression.

Indexed as

Carcinoma, Renal CellEukaryotic Initiation Factor-4AKidney NeoplasmsLung NeoplasmsRNA, CircularRNA, Long NoncodingAnimalsCell Line, TumorCell MovementCell ProliferationDEAD-box RNA HelicasesDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceMice, NudeDEAD-box RNA HelicasesEIF4A3 protein, humanEukaryotic Initiation Factor-4APVT1 long-non-coding RNA, humanRNA, CircularRNA, Long NoncodingaxitinibcircPVT1cP104aaEIF4A3renal cell carcinoma

Identifiers

PMID40966379
PMCPMC12752572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.